John Divine

John Divine

John Divine is currently an investing reporter at U.S. News & World Report, and was previously an assistant editor at InvestorPlace.com. He has worked variously in the fields of commercial real estate, money management and digital media, working as a financial journalist for most of his professional career.

John has also been a regular contributor to The Motley Fool, and his work also has appeared on AOL DailyFinance.

In 2013, he shortened his bucket list when he saw Warren Buffett live and in the flesh while covering the Berkshire Hathaway Annual Shareholders’ Meeting.

A proud North Carolinian and graduate of Appalachian State University, John majored in Finance & Banking. He enjoys basketball, reading, writing and food. He does not care for the Oxford comma, and he does not require the food he enjoys to be nutritious.

Recent Articles

Rumors: Google (GOOG) Is Looking to Buy Twitter (TWTR) Stock

Rumors are swirling that Google (GOOG) is looking to buy out Twitter (TWTR), sending Twitter stock roaring higher on Tuesday.

Is Axalta Coating (AXTA) Stock a Buy After Warren Buffett’s Big Bet?

Warren Buffett bought 20 million shares of Axalta Coating Systems (AXTA) stock yesterday. Should you buy the stock before he potentially doubles down?

Zulily (ZU) Stock: Why It’s a Screaming Buy Right Now

Don't count this e-tailer out just because ZU stock has imploded over the last year. A furious rally is in the works.

Sell Petrobras (PBR) Stock on the Rebound — It’s Still a Rip-Off

Petrobras (PBR) stock is rebounding from recent lows, but there are still glaring problems with the company itself. Sell now before it turns sour yet again.

Dyax (DYAX) Stock: Meteoric Rally After Blowout Clinical Trial

Dyax (DYAX) stock is up more than 50% in Tuesday trading after its preventive HAE treatment, DX-2930, performed well in clinical trials.